Julie Silverstein

1158 Disparities in Protocol Exposure and Outcomes of TNTS Resection for Cushing’s Disease: A Multi-Institutional Analysis

Jorge E. Salcedo-Sifuentes, Carter M. Suryadevara, Andrew Little, Ildiko Torok et autres

380 Biochemical Profiles of Cushing’s Disease by Race and Ethnicity: A Multi-institutional Analysis

Jorge E. Salcedo-Sifuentes, Carter M. Suryadevara, Andrew Little, Ildiko Torok et autres

Comparative Hypothalamic and Endocrinological Outcomes of Craniopharyngiomas Based on Infundibulum Sacrifice vs. Preservation: A Retrospective, Multi-center Rapid Consortium Study

Brandon Laing, Francesca Ghidoni, Noa Tal, Daniel Kelly et autres

us (code pays fourni par la source)

Corrigendum to “Medical treatment of hypercortisolism with relacorilant: Final results of the phase 3 GRACE study” [American Heart Journal 278S (2024) Pages 10-11]

Rosario Pivonello, Giorgio Arnaldi, Richard J. Auchus, Corin Badiu et autres

Development and validation of clinical screening systems for Cushing disease in the United States

Jorge E. Salcedo-Sifuentes, Sonal Mehta, Carter M. Suryadevara, Marvin Bergsneider et autres

us (code pays fourni par la source)

OR12-04 Clofutriben, an 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor, vs Placebo in a Phase II Trial for ACTH-dependent Cushing’s Syndrome (RESCUE)

Maria Fleseriu, Corin P Badiu, Irina Bancos, Eliza B. Geer et autres

us, ro, bg (code pays fourni par la source)

MON-088 Effects Of Relacorilant On Pituitary Tumor Volume In Patients With Cushing Disease: Results From The Phase 3 Grace Study

Georgiana Dobri, Giorgio Arnaldi, Richard J. Auchus, Corin Badiu et autres

us, ar, ro, nl, at, it, es, de (code pays fourni par la source)

OR12-05 Effects of Relacorilant on Body Weight and Body Composition in Patients With Endogenous Hypercortisolism in the Phase 3 GRACE and GRADIENT Studies

Oksana Hamidi, Richard J. Auchus, Robert S. Busch, Honey E. East et autres

us, nl, pl, by, it, de (code pays fourni par la source)

SUN-097 CAM2029 Octreotide Subcutaneous Depot Maintains Control of IGF-I and Symptoms of Acromegaly Across the 4-Week Dosing Interval and During Intervals Greater Than 28 Days: Data from the ACROINNOVA 1 Trial

Mônica R. Gadelha, Beverly M. K. Biller, Maria Fleseriu, Joanna L. Spencer-Segal et autres

br, us, se, it (code pays fourni par la source)

The evolution and application of multi-omic analysis for pituitary neuroendocrine tumors

Sangami Pugazenthi, Shree S. Pari, Ziyan Zhang, Julie Silverstein et autres

us (code pays fourni par la source)

Early Findings from the Multicenter RAPID Consortium on Papillary Craniopharyngiomas

Michael P. Catalino, D. T. Pham, Robert C. Rennert, William T. Couldwell et autres

us (code pays fourni par la source)

Management of Osilodrostat Therapy in Patients With Cushing's Syndrome: A Modified Delphi Consensus Panel

Susan L. Samson, Diane Donegan, Eliza B. Geer, Murray B. Gordon et autres

us (code pays fourni par la source)